Industry Overview

Pen needle market was valued at $2.2 billion in 2025 and is projected to reach $4.4 billion by 2035, growing at a CAGR of 6.4% during the forecast Period (2026-2035). The market growth is driven by the rising prevalence of diabetes and chronic diseases, a global shift towards convenient self-administered drug delivery, technological advancements (like finer, safer needles), and increasing healthcare expenditure, especially in emerging markets. Key factors fueling demand include patient preference for user-friendly devices, favorable reimbursement policies, and innovation in needle design (e.g., shorter lengths like 4mm), while challenges involve high costs and regulatory hurdles, with Asia-Pacific showing significant growth potential.

Market Dynamics

Increasing Prevalence of Genetic and Chronic Diseases Driving Early Detection Demand

One of the most significant drivers of the global genetic testing market is the rising incidence of genetic disorders and chronic diseases such as cancer, cardiovascular conditions, diabetes, and rare hereditary ailments. As these conditions become more widespread worldwide, both patients and healthcare providers are placing greater importance on early detection and diagnosis to improve outcomes and reduce long-term treatment costs. Genetic testing enables identification of predispositions to diseases long before symptoms appear, which is especially crucial for hereditary cancers like BRCA-linked breast and ovarian cancer, Huntington’s disease, and other genetic abnormalities. This push toward early intervention is increasing the routine use of genetic screening as part of standard clinical practice.

Technological Advancements and Integration with Personalized Medicine

Technological innovation is another core driver fueling market growth. Advances in high-throughput platforms, especially next-generation sequencing (NGS), along with improved PCR, microarray technologies, and bioinformatics tools, have dramatically enhanced the speed, accuracy, and affordability of genetic tests. These innovations have expanded the clinical utility of genetic testing into areas such as precision medicine, oncology, pharmacogenomics, and reproductive health. Personalized medicine, which tailors treatment based on an individual’s genetic profile, is increasingly integrated into healthcare systems, prompting clinicians to use genetic data for tailored therapies and more effective clinical decisions. This trend not only boosts demand from hospitals and diagnostic labs but also encourages collaborations between testing companies and healthcare providers.

Growing Awareness, Accessibility, and Direct-to-Consumer Adoption

A third pivotal driver is the expansion of genetic testing awareness and accessibility, especially driven by direct-to-consumer (DTC) offerings and public health education. Consumers are becoming increasingly proactive about their health, seeking genetic insights for disease risk assessment, wellness planning, and ancestry exploration. At-home kits from companies like 23andMe and others have made genetic testing more accessible outside traditional clinical environments, democratizing genomic insights and sparking broader public interest. Additionally, improved digital platforms, tele-genetics services, and supportive reimbursement policies are lowering barriers to adoption, particularly in emerging markets. As public familiarity and acceptance grow, so does the uptake of genetic tests across diverse population segments.

Market Segmentation

• Based on the type, the market is segmented into standard pen needles and safety pen needles.
• Based on the therapy, the market is segmented into insulin, GLP-1 and growth hormones.
• Based on the purchase, the market is segmented into retail and non-retail.

Standard Pen Needles Segment to Grow at a Considerable Market Share

Standard pen needles used for insulin therapy represent the single largest segment and are expected to lead the market with the highest revenue share. This dominance is primarily driven by the global rise in diabetes prevalence, which has made insulin administration a routine, lifelong requirement for millions of patients worldwide. Standard pen needles remain widely preferred due to their cost-effectiveness, broad availability, ease of use, and compatibility with most insulin pens, particularly in high-volume markets such as North America, Europe, and Asia-Pacific. Compared to safety pen needles, standard variants are more commonly adopted in both retail and non-retail settings, especially in emerging economies where price sensitivity strongly influences purchasing decisions. The consistent and recurring demand for insulin delivery, supported by expanding diabetic populations and increasing insulin adoption in type-2 diabetes management, firmly positions standard insulin pen needles as the largest and most influential segment across the overall market.

Insulin: A Key Segment in Market Growth

Insulin segment emerges as the primary growth driver. Insulin continues to dominate due to the rising prevalence of diabetes globally, especially type 2 diabetes, which accounts for the majority of cases. The World Health Organization and International Diabetes Federation report that diabetes cases are increasing steadily across both developed and emerging economies, creating sustained demand for insulin therapies. Advances in insulin delivery technologies, including pre-filled pens, smart insulin pumps, and rapid-acting formulations, are enhancing patient compliance and convenience, further driving adoption.

Additionally, rising awareness of glycemic control and long-term management among patients and healthcare providers contributes to consistent market expansion. Retail channels, including pharmacies and online platforms, complement this growth by improving accessibility, particularly in regions where chronic disease management infrastructure is evolving. Combined with government initiatives to improve diabetic care, reimbursement policies, and support for chronic disease management, the insulin segment’s dominance is expected to persist, making it the key contributor to overall market revenue growth in the coming years. This trend underscores the segment’s pivotal role in shaping market dynamics across therapeutic areas, particularly in regions with increasing diabetes prevalence, such as North America, Europe, and Asia-Pacific.

Regional Outlook

The global pen needle market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US is the undisputed leader in the global genetic testing market, capturing the largest share and driving overall industry growth. This dominance is primarily attributed to the country’s advanced healthcare infrastructure, widespread adoption of cutting-edge diagnostic technologies, and significant investment in genomic research and precision medicine initiatives. The U.S. also benefits from favorable reimbursement policies for genetic tests, which incentivize healthcare providers and patients to utilize screening services for early disease detection, particularly in oncology, prenatal care, and rare genetic disorders.

Additionally, the presence of major market players, including Illumina, Thermo Fisher Scientific, Myriad Genetics, and Quest Diagnostics, has created a highly competitive environment that fosters continuous innovation and product development. The growing direct-to-consumer (DTC) genetic testing market is another key factor, with companies like 23andMe expanding access to genetic insights for health, wellness, and ancestry purposes, further boosting market penetration. High consumer awareness regarding personalized medicine and proactive health management also contributes to rapid adoption of genetic tests. Together, these factors position the United States not only as a technological and commercial leader but also as a benchmark for market trends that influence global adoption, pricing, and development strategies across the genetic testing landscape.

Market Players Outlook

The major companies operating in the global pen needle market include BD (Becton, Dickinson and Company), Novo Nordisk A/S, Owen Mumford Ltd.,Terumo Corp.,Qiagen N.V., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In October 2025, Sandstone Medical launched its Easydrip Plus pen needles in Turkey through a prominent diabetes distributor, attracting interest from nearby Middle-Eastern markets. Key advantages include a bridge between premium and low-end options, an advanced large-platform design, ISO 13485 and CE certification, and availability in hospitals and pharmacies. The hexagonal hub design stabilizes the pen during insertion, reducing wobble and bruising. Additionally, the enlarged contact surface enhances dosing confidence, and the thin-wall cannula with silicone lubrication minimizes penetration force for a gentler injection experience.
• In August 2025, Trividia Health launched its TRUEplus five-bevel insulin pen needles in the UK, offering a range of needle gauges and sizes at competitive prices for diabetes patients. Designed for comfort and ease of use, these needles aim to improve the experience of insulin injections and enhance patient acceptance. The new needles are the lowest-priced five-bevel options available on prescription, contrasting with older three-level designs that may be less comfortable. This launch marks the first time these needles are available outside of the US, where they are already sold under the TRUEplus brand and various retail pharmacy brands.
• In August 2024, MTD Group acquired Ypsomed's Pen Needles and Blood Glucose Monitoring Systems, which is expected to elevate MTD's production capacity to over 2.5 billion units. This acquisition will enhance MTD’s diabetes and obesity care portfolio by integrating Ypsomed's operations into its European network. MTD plans to invest in new production facilities in Europe to improve capacity, quality, and ESG credentials. The growth in demand is driven by the increasing prevalence of diabetes, advancements in needle technology, an aging population, preference for self-administration, rising obesity rates, and the impacts of the global pandemic.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global pen needle market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.